5.1.2 Cephalosporins, carbapenems, and other beta-lactams

5.1.2.1 Cephalosporins

Cefalexin
  • Capsules 250mg, 500mg (£1.82, £1.99 = 28 pack)
  • Suspension 125mg/5ml, 250mg/5ml (£0.84, £1.40 = 100ml)

Indications

Ceftriaxone
  • Injection 250mg, 1g, 2g vial (£9.58 = 1g vial)

Indications

Notes

  1. MHRA Drug Safety Update (October 2009): Ceftriaxone should not be given simultaneously with calcium containing solutions (other than total parenteral nutrition solutions) for IV administration because of the risk of calcium precipitation. Ceftriaxone is contraindicated in newborns up to age 28 days who need IV treatment with any calcium containing solution. Calcium and ceftriaxone may be infused sequentially in patients aged 28 days or older provided that either the infusion line is rinsed or flushed between solutions, or the infusions are given via different infusion lines at different sites.
Cefixime
  • Tablets 200mg (£13.23 = 7 pack)

Indications

Cefuroxime
  • Tablets 250mg (£17.72 = 14 pack)
  • Injection 250mg, 750mg, 1.5g
Cefradine
  • Capsules 250mg, 500mg
Ceftazidime
  • Injection 250mg, 500mg, 1g, 2g, 3g

5.1.2.2 Carbapenems

Ertapenem
  • IV Infusion 1g vial
Meropenem
  • Injection 500mg, 1g

5.1.2.3 Other beta-lactam antibiotics

Aztreonam
  • Injection 1g, 2g
  • Powder for nebuliser solution (solvent and nebuliser handset) 84 x 75mg vials

Notes

  1. Aztreonam is included for resistant pseudomonal infection in cystic fibrosis patients.

 

Home > Formulary > Chapters > 5. Infections > 5.1 Antibacterial drugs > 5.1.2 Cephalosporins, carbapenems, and other beta-lactams

 

  • First line
  • Second line
  • Specialist
  • Hospital